COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
COVID-19 has rapidly evolved into a generalized global pandemic. Post-exposure prophylaxis
(PEP) against on COVID-19 was identified as an urgent research priority by the WHO, and
lopinavir/ritonavir (LPV/r) is a promising candidate for both COVID-19 treatment and PEP,
with a good safety profile and global availability. This is a cluster randomized controlled
trial (RCT) of oral LPV/r as PEP against COVID-19, that will address the immediate need for
preventive interventions, generate key data on COVID-19 transmission, and serve as a research
platform for future vaccines and preventive agents.